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Background: To report our results with postoperative or definitive radiation therapy in head and neck sarcomas.
Methods: We performed a retrospective analysis of 26 patients suffering from head and neck sarcomas, who
received postoperative or definitive radiation therapy between 2003 and 2012. Median age was 64 years (19–88)
and 69 % were male. Tumor locations were skull (including skin) in 31 %, paranasal sinus/orbita in 27 % and neck
(including pharynx/larynx) in 42 %. Median tumor size was 4.6 cm (1-12 cm). 22 patients (85 %) presented in
primary situation. Stage at presentation (UICC 7th for soft tissue sarcomas) was as follows: Ia:4 %, IIa:50 %, IIb:15 %,
III:31 %. All except one patient suffered from high grade lesions (G2/3 FNCLCC), predominantly angiosarcoma
(35 %), MFH (19 %) and synovial sarcoma (15 %). Surgery was performed in 21 pts (81 %), resulting in free margins
in 10 (38 %), microscopically positive margins in 6 (23 %) and gross residual disease in 5 (19 %). Median dose to the
primary tumor region was 66Gy (45-72Gy) in conventional fractionation, using 3D-CRT in 65 %, IMRT in 27 % and
electrons in 8 %. 50 % of the patients also received sequential chemotherapy.
Results: Median follow up was 39 months (8–136). We observed three local recurrences, transferring into estimated
3- and 5-year local control rates of 86 %. One additional patient failed distantly, resulting in 3- and 5-year freedom
from treatment failure rates of 82 %. Four patients have deceased, transferring into 3- and 5-year overall survival
rates of 88 % and 82 %, respectively. Only two of the four deaths were sarcoma related. Maximum acute toxicity
(CTCAE 3.0) was grade 1 in 27 % of the patients, grade 2 in 50 % and grade 3 in 23 %. Severe acute toxicity was
mainly represented by mucositis and dysphagia. Maximum late toxicity was grade 1 in 31 %, grade 2 in 15 % and
grade 3 in 19 % of the patients. Severe late toxicity included skin ulceration (n = 1), dysphagia with persistent tube
dependency (n = 1), persistent sinusitis (n = 1) and hearing loss (n = 2).
Conclusion: Excellent local control and overall survival rates can be achieved with postoperative or definitive
radiation therapy with acceptable acute and late toxicities in patients suffering from sarcomas of the head and
neck region.Background
Soft tissue sarcoma of the head and neck is a very rare dis-
ease, given the fact that soft tissue sarcomas represent less
than 1 % of all malignancies in adults [1] and only 5–10 %
of them are located in the head and neck region [2]. Be-
cause of this rarity, evidence from randomized trials or* Correspondence: Falk.Roeder@med.uni-muenchen.de
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creativecommons.org/publicdomain/zero/1.0/prospective studies is almost absent [3]. Treatment rec-
ommendations are mainly based on data from trials per-
formed in extremity sarcomas [4], although achievement
of local control seems more critical with regard to overall
survival [3, 5] in the head and neck region than in other
sites. Surgery remains the cornerstone of curative intent
treatment [5], however wide margins are often difficult to
achieve due to the proximity of crucial structures or inac-
ceptable functional outcome. Therefore postoperative ra-
diation therapy has been advocated by some authors [3, 6]
based on the clear evidence for improved local controlticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Patient and treatment characteristics
Table 1 n % n %
Gender Age
Male 18 69 Median 64 years
Female 8 31 Range 19–88 years
Situation Size
Primary 22 85 Median 4.6 cm
Recurrent 4 15 Range 1–12 cm
Location Grading
Skull* 8 31 1 1 4
Sinus/orbit 7 27 2 8 31
Neck‘ 11 42 3 17 65
Histology T stage
Angiosarcoma 9 35 1a 4 15
MFH/undiff. pleo. 5 19 1b 10 38
Synovial 4 15 2b 12 46
Other 8 31
N stage CHT
N0 24 92 Yes 13 50
N1 2 8 None 13 50
Clinical stage Surgery
Ia 1 4 R0 10 38
IIa 13 50 R1 6 23
IIb 4 15 R2 5 19
III 8 31 None 5 19
RT dose (PT) ENI
Median 66 Gy Yes 14 54





*: includes skin, ‘: includes larynx/pharynx, MFH: malignant fibrous
histiocytoma, undiff. pleo.: undifferentiated pleomorphic sarcoma, RT: radiation
therapy, PT: primary tumor region, 3D-CRT: 3d-conformal radiation therapy,
IMRT: intensity-modulated radiation therapy, cm: centimeter, CHT:
chemotherapy, ENI: elective nodal irradiation (ipsilateral cervical nodes)
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sarcomas [7]. In cases without the possibility of gross total
resection, definitive high dose radiation therapy seems to
be the best local treatment option [8]. However, no gener-
ally accepted standard for target volume definition and dose
prescription in this particular entity exists. Here we present
our experience with postoperative or definitive radiation
therapy in head and neck sarcoma cases.
Methods
We performed a retrospective analysis of 26 patients suffer-
ing from head and neck soft tissue sarcomas without dis-
tant spread, who were treated with postoperative or
definitive radiation therapy at our institution between 2003
and 2012. Patients with dermatofibrosarcoma protuberans
(DFSP) or desmoid tumors were excluded. Median age was
64 years and 69 % of the patients were male. 22 patients
(85 %) presented in primary situation while four had
already recurrent tumors. Tumors were located in the skull
in 31 %, paranasal sinus/orbita in 27 % and neck (including
pharynx/larynx) in 42 % of the patients. Median tumor size
was 4.6 cm. All except one patient suffered from high grade
lesions (G2/3 according to FNCLCC), predominantly
angiosarcoma (35 %). Clinical stage at presentation (accord-
ing to UICC 7th edition for soft tissue sarcomas) was Ia in
4 %, IIa in 50 %, IIb in 15 % and III in 31 % of the patients.
For detailed patients characteristics see Table 1.
Surgery was performed in 21 (81 %) patients and re-
sulted in free margins in 10 (38 %), microscopically
positive margins in 6 (23 %) and gross residual disease
in 5 (19 %) patients. 5 (19 %) patients were judged pri-
marily unresectable. Radiation therapy was performed
either postoperatively or definitively. Due to the long
time period covered by this study, target delineation, ra-
diation technique and dose varied to some extent. Usu-
ally patients were treated in supine position, using a
thermoplast head mask and multiple field techniques
(3D-conformal RT or IMRT). The initial PTV usually
included the surgical bed/gross tumor volume with a
safety margin of 2–3 cm and was irradiated up to 50–
50.4 Gy in conventional fractionation (1.8–2.0 Gy single
dose). In patients with node positive disease, after ipsi-
lateral neck dissection or histologies known for in-
creased risk of nodal spread (e.g. synovial sarcoma,
angiosarcoma), the ipsilateral cervical lymph nodes were
included into the initial PTV. The boost PTV usually in-
cluded the surgical bed/gross tumor volume with a
safety margin of 1–2 cm and received 10–20 Gy accord-
ing to resection margin. Margins could be reduced at
anatomical borders like uninvolved bony structures or in
case of directly adjacent organs at risk with low radiation
tolerance at the discretion of the treating radiation oncolo-
gist. Half of the patient additionally received pre- or postop-
erative sequential chemotherapy (mainly doxorubicin and/or ifosfamide) at the discretion of the treating medical on-
cologist. For detailed treatment characteristics see Table 1.
Regular follow-up took place at our institution or at the
referring center and included at least clinical examination,
CT or MRI of the head and neck area and scoring of tox-
icity. In case of evidence for local or distant spread, add-
itional tests were performed at the discretion of the
treating physician to confirm or rule out treatment failure.
Local control (LC) was defined as absence of tumor re-
growth in the head and neck area. Freedom from treat-
ment failure (FFTF) was defined as absence of local or
distant failure. All time to event data was calculated from
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Kaplan-Meier method. Acute and late toxicities were
scored according to CTCAEV3.0. No subgroup analyses
were performed due to the small sample size. The study
was in accordance to the declaration of Helsinki in its lat-
est version.
Results
Median follow up for the entire cohort was 39 months
(range 8–136 months). Three patients (12 %) developed
local recurrences after 14, 17 and 22 months, transfer-
ring into estimated 3- and 5-year local control rates of
86 % (see Fig. 1). One additional patient failed distantly
(at multiple sites) after 10 months, resulting in 3- and 5-
year freedom from treatment failure rates (FFTF) of
82 % (see Fig. 2). Four patients (15 %) have deceased,
transferring into 3- and 5-year overall survival rates of
88 % and 82 %, respectively (see Fig. 3). Only two of the
four deaths were sarcoma related.
Acute radiation related toxicities consisted mainly of
dermatitis, mucositis and dysphagia, but were generally
mild. The maximum acute toxicity was grade 1 in 27 %,
grade 2 in 50 % and grade 3 in 23 % of the patients. No
grade 4/5 acute toxicities were observed. For detailed acute
side effects see Table 2. Late radiation related toxicities were
even less pronounced and did not show a distinct pattern.
Maximum late toxicity was grade 1 in 31 %, grade 2 in
15 % and grade 3 in 19 % of the patients. Severe late sideFig. 1 Local control (LC)effects included skin ulceration (1), dysphagia with persist-
ent tube dependency (1), persistent sinusitis (1) and hearing
loss (2 patients). No grade 4/5 late toxicities have been ob-
served. For detailed late toxicities see Table 3.
Discussion
Soft tissue sarcomas of the head and neck are a very rare
entity, usually treated with surgery and/or radiation therapy
[6]. In our current series, we evaluated 26 patients who had
received postoperative or definitive radiation therapy to a
median dose of 66 Gy and found an encouraging 5-year-LC
rate of 86 % and a 5-year-OS rate of 82 %. These results
seem to compare favourably with many other series, which
reported 5-year LC rates of 41 %-83 % [2, 5, 9–18] and 5-
year survival rates of 56 %-75 % [2, 5, 9–18]. However, care
must be taken when interpreting and comparing different
series of head and neck sarcomas. Most available data is
based on retrospective analyses including small numbers of
patients and covering long time periods. Variations in
pathologic subsite, site of tumor involvement, local tumor
extent, percentage of gross total resections, percentage of
irradiated patients and histologic grade are all factors with
impact on outcome [6]. For example, Mattavelli et al. [5] re-
ported on 167 patients of whom the vast majority received
gross total resection (94 %) without adjuvant therapy
(66 %). They reported encouraging 10-year local recurrence
and disease-specific mortality rates of 19 % and 26 %, re-
spectively. However, 35 % of the included patients suffered
Fig. 2 Freedom from treatment failure (FFTF)
Fig. 3 Overall survival (OS)
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Table 2 Acute radiation-related toxicities, multiple toxicities in
same patient possible
Table 2 All grades Grade 3
n % n %
Skin 24 92 3 12
Mucositis 16 62 2 8
Dysphagia 16 62 4 15
Otitis/Hearing 3 12 1 4
Hoarseness 6 23
Nausea 3 12
Dry eye 3 12
Epistaxis 2 8
Leukopenia 10 39 1 4
Anemia 15 57
Thrombopenia 2 8
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minimally contributed to the occurrence of any events [5].
If those patients were excluded, 10-year LR and DSM
rates increased to 27 % and 39 %, respectively. Le et al.
[15] reported a series of 65 patients, of whom less than
half received gross total resection but were postoperatively
irradiated in the majority of cases (78 %). In the 54 pa-
tients treated with curative intent, they achieved 5-year
local control and overall survival rates of 66 % and 64 %,
respectively. Willers et al. [10] analyzed 57 patients, who
were treated with radiation therapy (with or without sur-
gery) and found 5-year local control rates of 60 % and
66 %, respectively. After exclusion of angiosarcomas, local
control and survival were improved to 69 % and 83 %. Re-
cently, Trifiletti et al. [18] reported a small series of 28 pa-
tients with mature follow up (median 11 years) of whomTable 3 Late radiation-induced toxicities, multiple toxicities in
same patient possible
Table 3 All grades Grade 3
n % n %
Skin 5 19 1 4
Lymph edema 3 12
Dysphagia 2 8 1 4
Xerostomia 8 31
Loss of taste 4 15
Hearing loss 3 12 2 8
Sinusitis 1 4 1 4
Hypothyreosis 1 4
Hoarseness 1 4
Dry eye 1 4
Skin infection* 1 4 1 4
Trismus 1 4
*Probably not related to radiationall received gross total resection and adjuvant radiation
therapy and found very encouraging 5-year LC and OS
rates of 83 % and 75 %, respectively. Given the inhomo-
geneous patient cohorts, it is difficult to assess the influ-
ence of treatment related factors like margin status or the
efficacy of adjuvant radiation therapy. In most series,
favourable, small, low grade tumors tended to be treated
with surgery alone, whereas unfavourable tumors with in-
complete resections were more likely to receive additional
radiation therapy [6]. However, there is a strong rationale
to add radiation therapy at least in the majority of pa-
tients: As known from randomized trials and large registry
studies, additional radiation therapy undoubtly increases
local control after wide excision in extremity sarcomas [7,
19, 20]. The absolute gain for the addition of radiation
therapy thereby increases with grade and narrowness of
the surgical margin [20]. As wide surgical margins are
often not achievable in head and neck cases due to the
proximity of vital structures and even gross residual dis-
ease will be present in a substantial proportion of patients
after surgery [6], additional radiation therapy should the-
oretically result in even more pronounced improvements
in local control as in extremity sarcomas. Consistently
with that assumption, most series reporting subgroup ana-
lyses showed at least improved local control rates for the
combination of surgery and radiation compared to surgery
alone, even considering an imbalance of prognostic factors
in favour of the surgery only group [13, 15, 16]. For ex-
ample Le et al. [15] reported 5-year local control rates of
59 % for surgery alone and 77 % for surgery and RT, al-
though the combined group included larger tumors and
more incomplete resections. Eeles et al. [16] observed 5-
year local control rates of 40 % for surgery alone and 60 %
for the combined treatment and described combination
treatment as a significant positive factor in multivariate
analysis for local control. Tran et al. [13] compared 94 pa-
tients treated with surgery with or without adjuvant radi-
ation at UCLA and observed a significant difference in
local control rate (52 % vs 90 %) in favour of adjuvant ra-
diation. They further analyzed the group according to
margin status and found the most pronounced difference
in patients with positive margins.
The achievement of local control is of crucial interest in
head and neck sarcomas because of the different pattern
of relapse compared to extremity sarcomas. Similarly to
the retroperitoneal space [21], many series showed that in
head and neck sarcomas local recurrence occurs more
often than distant relapse and represents the major cause
of death because salvage surgery is often limited [3]. For
example in the series of Mattavelli et al. [5], 25 of the 35
locally recurrent patients died as a consequence of their
relapse and the authors concluded that more patients
were lost due to local than due to distant progression.
Eeles et al. [16] described 46 sarcoma related deaths in
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by distant progression. Le Vay et al. [9] described that 68 %
of sarcoma related deaths were caused by uncontrolled
local relapse. Willers et al. [10] found an even higher per-
centage of 74 % in their series. Correspondingly, the rate of
distant failures seems lower than in extremity sarcomas ac-
cording to most series. Kraus et al. [6] reviewed the litera-
ture and found rates of 0–9 % for distant metastases at
presentation and 9–31 % for subsequent distant failure after
treatment of initially locoregionally confined disease.
Because of the rarity of head and neck sarcomas, no
generally accepted dose and target volume concept exists
for adjuvant or definitive radiation therapy. Usually the
treatment of the tumor bed after surgery with generous
margins is recommended based on the experience from
extremity sarcomas. Dose concepts also follow the recom-
mendations for extremity tumors, but are often difficult to
achieve due to adjacent radiosensitive organs at risk. In
general 60–70 Gy are recommended by most authors de-
pending on margin status [6]. In our series we used doses
of 45–72 Gy with a median dose of 66 Gy. Attempted
doses were 60–72 Gy according to margin status. With
this dose concept we observed acceptable rate of severe
acute (grade 3: 23 %) and late (grade 3: 19 %) side effects.
No grade 4/5 toxicities were found. Based on the experi-
ence in extremity sarcomas, growing evidence for a dose-
effect relationship exists regarding local control but also
toxicity [22]. For example, Zagars et al. [23] found im-
proved local control rates after gross complete resection
with doses of 64–68 Gy compared to 60 Gy. Fein et al.
[24] demonstrated improved local control rates if doses of
65 Gy or more were used. For gross residual disease, even
higher doses have to be attempted to achieve durable local
control at least in a substantial proportion of patients. For
example, Tepper et al. [25] found a significantly improved
local control rate with doses of more than 64 Gy in a
series of unresectable soft tissue sarcomas. Slater et al.
[26] described longer duration of local control after doses
exceeding 65 Gy and Kepka et al. [8] reported significantly
improved local control, disease-free survival and overall
survival rates in unresectable soft tissue sarcoma patients
treated with doses of 63 Gy or more. They confirmed their
results in a multivariate analysis and calculated an improve-
ment of 3 % per Gy in the 5-year local control and overall
survival rate. However, possible improvements in local con-
trol by dose-escalation have to be weighed against toxicity
and functional outcome. For example Mundt et al. [27] ob-
served a severe complication rate of 0 % for doses < 63 Gy
compared to 23 % with doses exceeding 63 Gy in grossly
resected soft tissue sarcomas. Stinson et al. [28] also de-
scribed significantly worse functional outcomes for doses of
more than 63 Gy. Kepka et al. [8] described a major com-
plication rate of 8 % for doses less or equal to 68 Gy com-
pared to 27 % for doses exceeding 68 Gy in unresectablesoft tissue sarcomas, and Slater et al. [26] observed 5 of 6
severe complications in patients treated with 70 Gy or
more. Although we could not establish any dose-effect re-
lationship in our series due to the small number of pa-
tients, we continue to use our margin-dependent dose
concept, attempting 60 Gy after resection with free mar-
gins, 66 Gy in cases with microscopic residual disease and
70–72 Gy if gross residual disease is present using the
dose constraints for organs at risk established in head and
neck cancer [29–34].
Clearly our study has some limitations, namely its retro-
spective nature, the small sample size and the relatively
short follow up. Nevertheless it shows very promising re-
sults in a rare patient group and therefore adds valuable
information to the existing literature.Conclusion
In summary, excellent local control and overall survival rates
with acceptable acute and late toxicities can be achieved
with postoperative or definitive radiation therapy. Achieve-
ment of local control seems of paramount importance be-
cause of the close relationship between local control and
survival in head and neck sarcomas. Therefore radiation
therapy should be added to surgery at least in high grade
sarcomas or patients with close or positive margins after
surgery despite the absence of randomized trials specifically
addressing this rare entity. Although we could not establish
a dose-effect relationship in our series, we continue to use
our margin-dependent dose concept, attempting 60 Gy after
resection with free margins, 66 Gy in cases with microscopic
residual disease and 70–72 Gy if gross residual disease is
present.
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